Medical Oncology   

Would you continue ibrutinib even if they are placed on anti-platelet therapy such as clopidogrel or ticagrelor? When do you switch to an altern...

Do you insist on ambulatory/home blood pressures to rule in/out white coat hypertension? Does your practice have a system to log patients' BPs to supp...

Is there a specific tyrosine kinase inhibitor that you would prefer to use?

For radiation oncologists, how do you ameliorate the risk for radiation-related injury to epicardial coronaries during treatment sessions?

If so, how long are they on degarelix before the switch? 

(i.e. frequency of serial BNP, troponin, cMRI)

How do you use this information in clinical practice?

E.g. in a patient with tenuous cardiac function, would starting treatment several weeks earlier potentially improve outcomes?

Do you feel comfortable with BTK inhibitors in these patients? In ELEVATE-RR patients on a/c were excluded, and rate of atrial fibrillation in the ac...

If no anthracycline, what alternative regimen would you consider? 

Is there any safety data to proceed with TKIs/TDM-1 or to proceed as standard with THP?

Do you repeat the loading dose of trastuzumab?

Would you even consider trabectedin in this case given its cardiotoxicity?

Patient does not want chemo but is tolerating these well otherwise. 

When 5FU is a backbone to so many regimens, when (if ever) do you consider re-challenging so as not to abandon an entire line of therapy?

Can these patients be re-challenged with Herceptin?

How does it vary for patients with a history of hypertension, diabetes, CHF, and coronary artery disease?

How might a recent (within 6 months) myocardial infarction affect your recommendations?